Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis

By A. Kontush, J. Chapman. Pharmacological Reviews, 2006

757 citations recorded by the source corpus.

Subfields: Clinical Biochemistry, Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/f4787479598ddac6ff068247c519c60c7965060d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Børge G. Nordestgaard
2. Jan Boren
3. A. Tybjærg-Hansen
4. Marja-Riitta Taskinen
5. L. Tokgözoğlu
6. I. Graham

In Surgery

1. Jan Boren
2. A. Tybjærg-Hansen
3. Børge G. Nordestgaard
4. Marja-Riitta Taskinen
5. L. Tokgözoğlu
6. I. Graham

Citations in the corpus

• Impact of Obesity and Metabolic Syndrome on Immunity. (2016, background): “This is because HDL serves as a carrier for a variety of oxidized lipid-neutralizing enzymes and bioactive lipid species, including paraoxonase 1, platelet-activating factor acetylhydrolase, lecithin-cholesterol acyltransferase, and sphingosine-1-phosphate (105).”
• Cholesterol efflux and atheroprotection: Advancing the concept of reverse cholesterol transport (2012, background): “However, HDL can become dysfunctional for example by posttranslational modification of apoA-I (46).”
• Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management (2011, background): “HDLs maintain endothelial vasoreactivity, attenuate oxidative stress, inhibit endothelial cell apoptosis, contribute to the repair of damaged endothelium,(61,62) inhibit monocyte activation,(63) and reduce the expression of adhesion molecules and cytokines.(28) Apo A–I may also immunoregulate lympho”